Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market
I'm PortAI, I can summarize articles.
Alec Stranahan from Bank of America Securities maintains a Buy rating on CG Oncology, Inc., with a $60 price target, citing the potential of their drug, cretostimogene, in treating NMIBC. The drug shows promise in both BCG-naïve and BCG-unresponsive settings, comparable to existing treatments. Strategic plans and a favorable safety profile support the positive outlook. LifeSci Capital also maintains a Buy rating with a $90 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments